Skip to content
Company Analysis

Ascendis Pharma A/S ASND

A comprehensive view of key metrics, scores, and financial health for Ascendis Pharma A/S

Overview of Ascendis Pharma A/S

ASND NMS
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Large Cap
Ascendis Pharma A/S (ASND), is a Large Cap company, in the Biotechnology industry, last closed at $249.55, about 92.0% overvalued vs fair value, +21.3% 1Y return, placing in the top 10% of its sector.
Metrics Rev Growth 98.0% ROE 169.8% Gross Margin 86.8%
USD 249.55
1.50%
(Delayed)
• Vol 90d: 38.3%
52-Week Range
Market Cap
$16.39B
Enterprise Value
$15.98B
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Excellent
Health
Good
Efficiency
Good
Valuation
Good
Growth
Good
Profitability
Excellent
Health
Good
Efficiency
Good
Valuation
Good
Completeness: 88%
Confidence: 91%
Updated: Oct 24
Top Beats

Quick Facts

Website https://ascendispharma.com
HQ Hellerup
Employees 1,189
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$18
$20
$22
Current: $249.55 -92% vs base

Engine Room Money Flow™

Large Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
EUR 616.0M
10.1%%
Total Revenue
EUR 720.1M
98%%
Net Income
-EUR 228.0M
39.7%%
Operating Expense
EUR 761.5M
27.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

R&D Intensity
39.9%
Fair

Moderate R&D intensity

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Ascendis Pharma A/S's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
56
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Cost Leadership Position Operating margin at 82.1th percentile with strong OpEx control demonstrates cost leadership.
  • Strong Interest Coverage & Conservative Leverage Debt serviceability is strong (score 0.87), with robust interest coverage.

Key risks

  • Liquidity Concerns Liquidity is concerning (score 0.12), raising questions about short-term obligations.
  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.33), suggesting weak customer stickiness.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
33
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Pre-Revenue Biotech vs Industry Peers 60% Coverage
Trade-Off Triangle Visualization A ternary plot showing ASND's balance between Growth (45.9%), Profitability (30.0%), and Safety (24.1%). Growth 46% Safety 24% Profitability 30%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

51th percentile vs peers
51
Key Signals
TSR -9.2% 51p
Strengths

No notable strengths identified for this axis.

Risks

No significant risks identified for this axis.

Profitability

- vs peers
-
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

26th percentile vs peers
27
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Ascendis Pharma A/S.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$19.91
- - -
-92.0% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000